More about Global Health Limited
Fundamentals for Global Health Limited
Regulatory Filings for Global Health Limited
The Hidden Cost of India's Electronics Assembly Push: A 40% E-Waste Surge and the Death of Affordable Repair
The Wedding Loan Trap: How India’s Microfinance Boom Turned Housewives Into Ghost Borrowers and Temple Brass Into EMI Cash
From Lifesaving Drugs to Sick Units: The Hidden Energy Crisis Inside India’s Pharma Clusters
From Price Pressures to Profit Power: The MSME Playbook Redefining India’s Economy
Fundamentals for Global Health Limited
Business Operations:
Sector: HealthcareIndustry: Medical Care Facilities
Global Health Limited engages in the provision of healthcare services in India. The company primarily offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, musculoskeletal disorders and orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, plastic, aesthetic and reconstructive surgery, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, ayurveda, and dietetics and nutrition. It also offers lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, blood bank and e-ICU services, and health plans, as well as operates pharmacies. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in New Delhi, India.
Revenue projections:
MEDANTA is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 42.786865 |
| debtToEquity | 25.468000 |
| earningsGrowth | -0.335000 |
| revenueGrowth | 0.188000 |
| grossMargins | 0.509300 |
| operatingMargins | 0.139250 |
| trailingEps | 19.130000 |
| forwardEps | 25.838540 |
MEDANTA's Debt-to-Equity ratio is low, indicating the company is not over-leveraged. This suggests a prudent approach to financing, with minimal dependence on debt, reducing the financial risk associated with high leverage, and signaling a stable financial outlook.
Global Health Limited's low earnings and revenue growth suggest that its profits could shrink. This points to a potential downturn in the company's financial outlook and may indicate challenges in maintaining profitability.
Global Health Limited's negative gross and operating margins indicate that the company is not generating profit from either production or day-to-day operations. This could suggest cost overruns or declining revenue, impacting its financial stability.
MEDANTA's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights MEDANTA's potential for increased earnings and a stronger financial performance in the upcoming year.
Price projections:
The price of MEDANTA has often been situated close to the lower end of projections. This consistent trend may signal difficulties for the company in achieving investor expectations for future performance.
Recommendation changes over time:
Analysts' buy bias for MEDANTA signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to MEDANTA, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
₹90 Crore Bet Signals a Massive Shift in India’s Rural Economy
The Hidden Engine of Global Growth: Why India Is Becoming Impossible to Overlook
₹10,000 Crore Deep-Tech Pivot: Why Fund of Funds 2.0 Will Redraw India's Startup Map